SRA Selects Oracle Adverse Event Reporting System
Oracle Health Sciences Application Chosen for Food and Drug Administration (FDA) Adverse Event Reporting System
Redwood Shores, CA-May 14, 2009
News Facts:
· In its role as prime contractor for the U.S. General Services Administration task order awarded in support of the FDA, SRA Corporation, a wholly owned subsidiary of SRA International, Inc., has selected the Oracle® Adverse Event Reporting System.
· Oracle Adverse Event Reporting System was selected as the solution that best met the requirements for a FDA Adverse Event Reporting System.
· Life Science organizations and regulators use the Oracle Adverse Event Reporting System to proactively manage the safety of both clinical and marketed products.
· The FDA is planning to use the application to help track safety issues and incidents once products are available on the market.
· As part of the evaluation criteria, the functional fit of the products were examined by assessing how well they met the system requirements.
· Products were also evaluated for their technical capability, including assessments of the following areas: performance and scalability; extensibility and flexibility; platform requirements; established methodologies for deployment; security; reliability and availability.
Supporting Quote
· “We are pleased to help the FDA meet its objective of acquiring a solution that provides post-market product safety surveillance capabilities as well as an improved methodology for submitting potential adverse events, analyzing individual safety and product quality reports, and delivering enhanced signal detection and management,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences. “We look forward
to working closely with SRA and the FDA to help make the FDA Adverse Event Reporting System project successful.”
Supporting Resources:
· SRA Recognized by Fortune as a Best Company to Work For
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
